The Hematology/Oncology Pharmacy Association (HOPA) has awarded two HOPA Research Grant Awards to Val Adams, PharmD, BCOP, FCCP, and Jill S. Bates, PharmD, MS, BCOP, for their respective research projects. The goal of HOPA’s Research Grant efforts are to fund work that results in facilitating the efforts of hematology/oncology pharmacists to optimize the care of individuals affected by cancer.
Cancer-Related VTE Study
Dr. Adams will receive $40,000 for his work entitled, “Cancer-related venous thromboembolism (VTE): Treatment choice, patterns, and outcomes.” This project will evaluate and compare anticoagulation treatments for cancer-related VTE. Recurrent VTE occurs in about 20% of patients, and major bleeds occur in up to 12% with a cancer-related VTE. This study will be the first to compare new treatment modalities to traditional anticoagulation treatment options.
Dr. Adams is Associate Professor in the Department of Pharmacy Practice and Science in the College of Pharmacy at the University of Kentucky. He is on the graduate faculty and is a member of the Markey Cancer Center. He chairs the protocol review and monitoring committee for the Cancer Center and is Director of the Hematology/Oncology Residency Program.
Oncology Pharmacy Research
Dr. Bates will receive $18,950 for research that aims to demonstrate that care provided to patients by oncology pharmacists positively impacts clinical outcomes and will establish a process of care in oncology pharmacy that empowers oncology pharmacists to step into a health-care provider role. The objective of this program is to establish pharmacist-patient relationships in an acute care oncology setting by providing a service that supports shared decision-making in cancer care, saves physician time, and reduces medication-related problems.
Dr. Bates is a clinical pharmacist practitioner focused in malignant hematology with the Department of Pharmacy at the University of North Carolina Medical Center (UNCMC). She also holds a position as Assistant Professor of Clinical Education in the Division of Practice Advancement and Clinical Education with the UNC Eshelman School of Pharmacy and is Director of the PGY2-Oncology Residency Program at UNC. ■